FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors

Share This Post

May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA approved an Investigational New Drug Application in January 2022 for the CAR-NK treatment FT536 to treat individuals with relapsed or resistant solid malignancies. In this trial, patients with advanced non-small cell lung cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, and pancreatic cancer will receive FT536 as a monotherapy or in combination with a monoclonal antibody. FT536 (Fate Therapeutics) is an allogeneic, multiple-engineered natural killer (NK) cell treatment produced from induced pluripotent stem cells.

This is a genetically engineered NK cell treatment that expresses a CAR that targets the alpha-3 domains of MICA and MICB, two proteins involved in the major histocompatibility complex class I. Both are stress proteins that are extensively produced in many solid tumours and can overcome shedding to restore tumour immunity mediated by NK and T cells. Overall, FT536 contains four functional modifications: a proprietary CAR targeting MICA and MICB’s 3 domain; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that enhances ADCC; promotes enhanced NK cells Active IL-15 receptor fusion (IL-15RF); and abrogation of CD38 expression, thereby enhancing NK cell metabolic fitness, persistence, and antitumor function.

We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid tumors, and it will be launched as soon as possible to benefit patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy